The endpoint of the strategy is a consistent, effective interaction between T cytotoxic CD8+ cells and cancer cells mediated via the T-cell receptor (TCR) and major histocompatibility (MHC)-type I molecules or tumor epitopes [16]. The gene discussed is HLA-C; the disease is neoplasm.